Method for treating ischemic conditions by administering drug by two routes

Claim 1

A method for the prophylaxis treatment of angina pectoris in human, which method consists essentially of: (a) placing on the skin of a human afflicted with angina pectoris a medical bandage consisting essentially of: (1) a reservoir consisting essentially of a composition consisting essentially of a gel formed of (i) a member selected from the group consisting of an inorganic oil and an organic oil, (ii) a cellulose in an amount sufficient to gel the oil, and (iii) a vasodilator drug in an amount sufficient for treating angina pectoris distributed throughout the gelled reservoir; (2) a membrane adjacent to one surface of the reservoir, one face of which forms the bottom of the bandage, the membrane formed of a vasodilator release rate controlling material that releases the vasodilator from the reservoir at a continuous and controlled rate over time; (3) a backing member substantially impermeable to the passage of drug adjacent to the opposite surface of the reservoir, one face of which forms the top of the bandage, and which backing member's edges overlay the edges of the reservoir and contact the edges of the rate controlling membrane in a fluid tight arrangement; (b) admitting orally into the human a pharmaceutical dosage form containing a vasodilator useful for treating angina pectoris; and, (c) administering transdermally the vasodilator and administering orally the vasodilator, and wherein the administrations lessen the therapeutically effective amount of vasodilator orally needed for treating the angina pectoris in the afflicted human.

Claim 2

A method for the prophylaxis treatment of angina pectoris in human, which method consists essentially of: (a) placing on the skin of a human afflicted with angina pectoris a medical bandage consisting essentially of: (1) a reservoir consisting essentially of a composition consisting essentially of a gel formed of (i) a member selected from the group consisting of an inorganic oil and an organic oil, (ii) a cellulose in an amount sufficient to gel the oil, and (iii) a vasodilator drug in an amount sufficient for treating angina pectoris distributed throughout the gelled reservoir; (2) a membrane adjacent to one surface of the reservoir, one face of which forms the bottom of the bandage, the membrane formed of a vasodilator release rate controlling material that releases the vasodilator from the reservoir at a continuous and controlled rate over time; (3) a backing member substantially impermeable to the passage of drug adjacent to the opposite surface of the reservoir, one face of which forms the top of the bandage, and which backing member's edges overlay the edges of the reservoir and contact the edges of the rate controlling membrane in a fluid tight arrangement; (b) admitting orally into the human a pharmaceutical dosage form containing a vasodilator useful for treating angina pectoris; and, (c) administering transdermally the vasodilator and administering orally the vasodilator, and wherein the administrations lessen the therapeutically effective amount of vasodilator orally needed for treating the angina pectoris in the afflicted human.

Claim 10

A method for lessening the incidence of anginal attacks by prophylaxis treatment, which method consists essentially of: (a) positioning topically on a patient prone to anginal attacks, a medical bandage consisting essentially of: (1) a membrane formed of a vasodilator release rate controlling polymer having one surface adapted for positioning the bandage on the patient; (2) a reservoir in contact with the opposite surface of the release rate controlling membrane, the reservoir consisting essentially of (i) a member selected from the group consisting essentially of a member selected from the group consisting of an inorganic and an organic oil, (ii) a polysaccharide in an amount sufficient to impart gel properties to the oil, and a dosage amount of a vasodilator in the gel; (3) a backing member having one surface that defines the top of the bandage and one surface in contact with the reservoir, the backing member formed of a material essentially impermeable to the passage of vasodilator, the edges of said backing member overlay the reservoir and contact the edges of the release rate controlling membrane in a fluid tight arrangement; (b) admitting internally into the patient a pharmaceutical dosage form containing a vasodilator drug useful for lessening the incidence of anginal attacks; and, (c) administering topically the vasodilator and administering internally the vasodilator with said administrations lessening the therapeutically effective amount internally needed for lessening the incidence of anginal attacks.

Claim 11

A method for lessening the incidence of anginal attacks by prophylaxis treatment, which method consists essentially of: (a) positioning topically on a patient prone to anginal attacks, a medical bandage consisting essentially of: (1) a membrane formed of a vasodilator release rate controlling polymer having one surface adapted for positioning the bandage on the patient; (2) a reservoir in contact with the opposite surface of the release rate controlling membrane, the reservoir consisting essentially of (i) a member selected from the group consisting essentially of a member selected from the group consisting of an inorganic and an organic oil, (ii) a polysaccharide in an amount sufficient to impart gel properties to the oil, and a dosage amount of a vasodilator in the gel; (3) a backing member having one surface that defines the top of the bandage and one surface in contact with the reservoir, the backing member formed of a material essentially impermeable to the passage of vasodilator, the edges of said backing member overlay the reservoir and contact the edges of the release rate controlling membrane in a fluid tight arrangement; (b) admitting internally into the patient a pharmaceutical dosage form containing a vasodilator drug useful for lessening the incidence of anginal attacks; and, (c) administering topically the vasodilator and administering internally the vasodilator with said administrations lessening the therapeutically effective amount internally needed for lessening the incidence of anginal attacks.